Core Viewpoint - Huadong Medicine's subsidiary has received acceptance for the marketing application of ZORYVE, a treatment for plaque psoriasis in patients aged 6 and above [1] Group 1 - Huadong Medicine's wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration [1] - The application for ZORYVE (0.3% Roflumilast Cream) is specifically for local external treatment of plaque psoriasis [1] - The treatment is indicated for patients aged 6 years and older, including those with intertriginous areas [1]